SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its...
Investment philosophy
Gilde Healthcare invests in businesses enabling better care at lower cost.
40
years in business
Venture&Growth
Gilde Healthcare Venture&Growth invests in healthtech and therapeutics. The Venture&Growth fund supports fast growing companies in Europe and North America.
68
Venture&Growth companies in portfolio
under management
2.6B
Private Equity
Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to the healthcare sector.
23
Private Equity companies in portfolio
portfolio
40
years in business
68
Venture&Growth companies in portfolio
under management
2.6B
23
Private Equity companies in portfolio
portfolio

Responsible Investment at Gilde Healthcare:
We focus on both ESG and Impact: ESG sets the foundation with responsible practices, while Impact drives measurable change in healthcare. Check out our impact cases to see how we’re making a difference.
Read more about ESG/impactNews
Keep up to date with Gilde Healthcare announcements and portfolio company news.